secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039052
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q2 revenue up 49% but net loss widens; multiple Phase 3 failures; new CEO appointed
--------------------------------------------------------------------------------

- Q2 total revenue $44.3M (+49% YoY); net loss $87.7M ($0.90) vs $72.6M ($0.78) last year; includes $24.6M one-time charge.
- Reported negative topline from three Phase 3 trials: MATTERHORN (roxadustat MDS), LELANTOS-1 (pamrevlumab DMD), ZEPHYRUS-1 (pamrevlumab IPF); ZEPHYRUS-2 discontinued.
- China roxadustat net sales $76.4M (+44% YoY) driven by >40% volume growth; number one anemia brand in China.
- Appointed Thane Wettig as Interim CEO; implemented cost reduction plan targeting $100-120M annualized GAAP expense savings.
- Exclusive license for FOR46 (FG-3246) ADC targeting CD46 for mCRPC; $75M non-dilutive term loan from Morgan Stanley.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/0000950170-23-039052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/fgen-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer